JP2015535259A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015535259A5 JP2015535259A5 JP2015539892A JP2015539892A JP2015535259A5 JP 2015535259 A5 JP2015535259 A5 JP 2015535259A5 JP 2015539892 A JP2015539892 A JP 2015539892A JP 2015539892 A JP2015539892 A JP 2015539892A JP 2015535259 A5 JP2015535259 A5 JP 2015535259A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antigen
- chitosan
- vaccine
- aldehyde
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 21
- 229960005486 vaccine Drugs 0.000 claims description 21
- 229920001661 Chitosan Polymers 0.000 claims description 16
- 239000000427 antigen Substances 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 150000001299 aldehydes Chemical class 0.000 claims description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- 244000005700 microbiome Species 0.000 claims description 8
- 239000002262 Schiff base Substances 0.000 claims description 6
- 150000004753 Schiff bases Chemical class 0.000 claims description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 5
- 230000005875 antibody response Effects 0.000 claims description 5
- 206010022000 influenza Diseases 0.000 claims description 5
- 231100000699 Bacterial toxin Toxicity 0.000 claims description 4
- 239000000688 bacterial toxin Substances 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 238000010791 quenching Methods 0.000 claims description 4
- 241000193403 Clostridium Species 0.000 claims description 3
- 241000223924 Eimeria Species 0.000 claims description 3
- 241000194017 Streptococcus Species 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 241000588807 Bordetella Species 0.000 claims description 2
- 102000009016 Cholera Toxin Human genes 0.000 claims description 2
- 108010049048 Cholera Toxin Proteins 0.000 claims description 2
- 241000588722 Escherichia Species 0.000 claims description 2
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 claims description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 241000204031 Mycoplasma Species 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- 241000607768 Shigella Species 0.000 claims description 2
- 241000191940 Staphylococcus Species 0.000 claims description 2
- 102000002689 Toll-like receptor Human genes 0.000 claims description 2
- 108020000411 Toll-like receptor Proteins 0.000 claims description 2
- 101710182223 Toxin B Proteins 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 2
- 244000144977 poultry Species 0.000 claims description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 2
- 229930182490 saponin Natural products 0.000 claims description 2
- 150000007949 saponins Chemical class 0.000 claims description 2
- 230000003248 secreting effect Effects 0.000 claims description 2
- 235000019832 sodium triphosphate Nutrition 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 229960000814 tetanus toxoid Drugs 0.000 claims description 2
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 claims description 2
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- 239000003651 drinking water Substances 0.000 claims 1
- 235000020188 drinking water Nutrition 0.000 claims 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- GUBGYTABKSRVRQ-PZPXDAEZSA-N 4β-mannobiose Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-PZPXDAEZSA-N 0.000 description 1
- 101710092462 Alpha-hemolysin Proteins 0.000 description 1
- 101710197219 Alpha-toxin Proteins 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 101100133212 Drosophila melanogaster NetB gene Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- DKXNBNKWCZZMJT-UHFFFAOYSA-N O4-alpha-D-Mannopyranosyl-D-mannose Natural products O=CC(O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O DKXNBNKWCZZMJT-UHFFFAOYSA-N 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 101710124951 Phospholipase C Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- -1 SagA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000002776 alpha toxin Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261719713P | 2012-10-29 | 2012-10-29 | |
| US61/719,713 | 2012-10-29 | ||
| PCT/US2013/067212 WO2014070709A1 (en) | 2012-10-29 | 2013-10-29 | Novel mucosal adjuvants and delivery systems |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015535259A JP2015535259A (ja) | 2015-12-10 |
| JP2015535259A5 true JP2015535259A5 (enExample) | 2016-12-22 |
| JP6284537B2 JP6284537B2 (ja) | 2018-02-28 |
Family
ID=50627985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539892A Active JP6284537B2 (ja) | 2012-10-29 | 2013-10-29 | 新規粘膜アジュバントおよびデリバリーシステム |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20150297714A1 (enExample) |
| EP (1) | EP2911676B1 (enExample) |
| JP (1) | JP6284537B2 (enExample) |
| KR (1) | KR102144602B1 (enExample) |
| CN (2) | CN109364244B (enExample) |
| AU (2) | AU2013338153B2 (enExample) |
| BR (1) | BR112015009541B1 (enExample) |
| CA (1) | CA2889841C (enExample) |
| CL (1) | CL2015001111A1 (enExample) |
| DK (1) | DK2911676T3 (enExample) |
| EA (2) | EA039237B1 (enExample) |
| ES (1) | ES2809220T3 (enExample) |
| HU (1) | HUE049965T2 (enExample) |
| MX (1) | MX380857B (enExample) |
| MY (2) | MY202024A (enExample) |
| NZ (1) | NZ708065A (enExample) |
| PH (2) | PH12015500956B1 (enExample) |
| PL (1) | PL2911676T3 (enExample) |
| PT (1) | PT2911676T (enExample) |
| SG (1) | SG11201503319UA (enExample) |
| WO (1) | WO2014070709A1 (enExample) |
| ZA (1) | ZA201503004B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101969990B (zh) * | 2007-11-01 | 2014-07-09 | 阿肯色大学评议会 | 增强针对艾美球虫属的免疫反应的组合物和方法 |
| DK2911676T3 (da) * | 2012-10-29 | 2020-08-03 | Univ Arkansas | Hidtil ukendte mukosale adjuvanser og afgivelsessystemer |
| US9603915B2 (en) | 2013-02-14 | 2017-03-28 | The Board of Trustees of the University of Akansas | Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection |
| BR112015023024B1 (pt) | 2013-03-15 | 2022-04-19 | The Board Of Trustees Of The University Of Arkansas | Vetor de vacina e composições farmacêuticas compreendendo o mesmo |
| DK3174553T3 (en) * | 2014-07-25 | 2018-07-23 | Biosynth Srl | GLYCOCOONJUGATE VACCINES INCLUDING BASIC UNITS OF A MOLECULE CONSTRUCTION THAT EXPRESSES MULTIPLE INTEGRATED EPITOPES FOR THE FORMULATION OF A WIDE-SPECTED VACCINE AGAINST INFECTIONS BASED ON BACTEROGEN |
| GB201522541D0 (en) * | 2015-12-21 | 2016-02-03 | Inst Research In Biomedicine | Compositions |
| KR102767638B1 (ko) | 2016-05-03 | 2025-02-20 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법 |
| WO2018225662A1 (ja) * | 2017-06-07 | 2018-12-13 | 出光興産株式会社 | 自然免疫増強剤 |
| CN111603566A (zh) * | 2019-02-25 | 2020-09-01 | 河南农业大学 | 一种靶向呼吸道黏膜的递呈载体复合物及应用 |
| WO2022256740A1 (en) | 2021-06-04 | 2022-12-08 | Curia Ip Holdings, Llc | Polymeric fusion proteins and compositions for inducing an immune response against infection |
| CN114134167A (zh) * | 2021-11-30 | 2022-03-04 | 山东邦盛达生物科技有限公司 | 具有粘膜免疫调节作用的重组枯草芽孢杆菌的制备方法及重组枯草芽孢杆菌和应用 |
| CN114288401B (zh) * | 2021-12-31 | 2023-10-03 | 四川农业大学 | 抗原蛋白的应用、引物组以及试剂盒 |
| JP2025510729A (ja) * | 2022-03-21 | 2025-04-15 | ユニバーシティ オブ サザン カリフォルニア | 三重ワクチンは、訓練免疫を介して細菌および真菌病原体に対して防御する |
| KR102743672B1 (ko) * | 2022-09-27 | 2024-12-17 | 전북대학교산학협력단 | 점막에서 항원 특이적 면역 반응을 증진시키는 신규한 펩타이드 및 상기 펩타이드를 유효성분으로 포함하는 점막 백신 보조제 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3501770A (en) * | 1967-04-13 | 1970-03-17 | Lilly Co Eli | Shipping fever vaccine |
| JP2546544B2 (ja) * | 1989-10-27 | 1996-10-23 | アーチ ディベラップメント コーポレイション | 免疫強化を促進するための方法と組成物 |
| CN1090022C (zh) * | 1995-04-04 | 2002-09-04 | 俄克拉荷马创伤治疗所 | 通过光动力疗法与免疫佐剂联合应用治疗癌症 |
| GB9725084D0 (en) * | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| AT410635B (de) * | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
| FI20010118A7 (fi) * | 2001-01-19 | 2002-07-20 | Carbion Oy | Uudet helicobacter pylori reseptorit ja niiden käyttö |
| NO317654B1 (no) * | 2002-05-03 | 2004-11-29 | Stiftelsen Biopolymer | Formulering som inneholder en nukleinsyre og et kitosan, fremgangsmate for fremstilling av formuleringen, samt anvendelser derav. |
| CA2555013C (en) | 2004-02-11 | 2013-10-15 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Carcinoembryonic antigen fusions and uses thereof |
| GB0405787D0 (en) * | 2004-03-15 | 2004-04-21 | Chiron Srl | Low dose vaccines |
| UA5098U (uk) | 2004-07-05 | 2005-02-15 | Михайло Валерійович Бабкін | Використання хітозану як ад'юванту |
| JP2008511611A (ja) * | 2004-08-30 | 2008-04-17 | ルナメツド・インコーポレーテツド | 治療用４−フェニル酪酸制御放出製剤 |
| BRPI0515316A (pt) * | 2004-09-14 | 2008-07-15 | Chiron Corp | compostos de imidazoquinolina |
| WO2006110915A2 (en) * | 2005-04-15 | 2006-10-19 | University Of Iowa Research Foundation | Vaccine formulations for leishmania |
| WO2007052058A1 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| CA2668693A1 (en) | 2006-11-15 | 2008-05-22 | David E. Anderson | Therapeutic uses of tim-3 modulators |
| WO2009056602A1 (en) * | 2007-10-30 | 2009-05-07 | Viscogel Ab | Chitosan composition |
| US8778384B2 (en) * | 2008-03-24 | 2014-07-15 | Advanced Bionutrition Corporation | Compositions and methods for encapsulating vaccines for the oral vaccination and boostering of fish and other animals |
| JP5339243B2 (ja) * | 2008-04-24 | 2013-11-13 | 株式会社微生物化学研究所 | ストレプトコッカス・スイス感染症予防用ワクチン |
| JP2010065027A (ja) * | 2008-08-12 | 2010-03-25 | Mie Univ | 魚類のウイルス性出血性敗血症に対する不活化ワクチンとその処方 |
| US8399635B2 (en) * | 2008-11-12 | 2013-03-19 | Synedgen, Inc. | Chitosan derivatives to treat animals or optimize animal health |
| EP2196196A1 (en) * | 2008-12-10 | 2010-06-16 | Medipol S.A. | Compound, medicament, vaccine composition and nanocapsules |
| JP5292141B2 (ja) * | 2009-03-17 | 2013-09-18 | シチズンマシナリーミヤノ株式会社 | タレット刃物台のクーラント供給構造 |
| WO2011057200A1 (en) * | 2009-11-06 | 2011-05-12 | Pharmasan Labs, Inc. | Preparing hapten-specific antibodies and their application for immunodiagnostics and research |
| EP2508212A1 (en) * | 2011-04-05 | 2012-10-10 | Universitätsklinikum Freiburg | Biocompatible and biodegradable gradient layer system for regenerative medicine and for tissue support |
| DK2911676T3 (da) * | 2012-10-29 | 2020-08-03 | Univ Arkansas | Hidtil ukendte mukosale adjuvanser og afgivelsessystemer |
-
2013
- 2013-10-29 DK DK13850423.8T patent/DK2911676T3/da active
- 2013-10-29 NZ NZ708065A patent/NZ708065A/en unknown
- 2013-10-29 EP EP13850423.8A patent/EP2911676B1/en active Active
- 2013-10-29 MX MX2015005444A patent/MX380857B/es unknown
- 2013-10-29 MY MYPI2018001431A patent/MY202024A/en unknown
- 2013-10-29 US US14/439,536 patent/US20150297714A1/en not_active Abandoned
- 2013-10-29 EA EA201891124A patent/EA039237B1/ru unknown
- 2013-10-29 MY MYPI2015001100A patent/MY190866A/en unknown
- 2013-10-29 EA EA201590829A patent/EA031234B1/ru unknown
- 2013-10-29 BR BR112015009541-0A patent/BR112015009541B1/pt active IP Right Grant
- 2013-10-29 ES ES13850423T patent/ES2809220T3/es active Active
- 2013-10-29 CA CA2889841A patent/CA2889841C/en active Active
- 2013-10-29 HU HUE13850423A patent/HUE049965T2/hu unknown
- 2013-10-29 AU AU2013338153A patent/AU2013338153B2/en active Active
- 2013-10-29 CN CN201811276098.8A patent/CN109364244B/zh active Active
- 2013-10-29 JP JP2015539892A patent/JP6284537B2/ja active Active
- 2013-10-29 PL PL13850423T patent/PL2911676T3/pl unknown
- 2013-10-29 CN CN201380068777.5A patent/CN104884069B/zh active Active
- 2013-10-29 KR KR1020157013782A patent/KR102144602B1/ko active Active
- 2013-10-29 WO PCT/US2013/067212 patent/WO2014070709A1/en not_active Ceased
- 2013-10-29 SG SG11201503319UA patent/SG11201503319UA/en unknown
- 2013-10-29 PT PT138504238T patent/PT2911676T/pt unknown
-
2015
- 2015-04-28 CL CL2015001111A patent/CL2015001111A1/es unknown
- 2015-04-29 PH PH12015500956A patent/PH12015500956B1/en unknown
- 2015-04-30 ZA ZA2015/03004A patent/ZA201503004B/en unknown
-
2016
- 2016-11-29 US US15/363,281 patent/US10258688B2/en active Active
-
2018
- 2018-09-18 AU AU2018232919A patent/AU2018232919B2/en active Active
-
2019
- 2019-04-09 US US16/379,535 patent/US10780162B2/en active Active
-
2020
- 2020-01-14 PH PH12020500101A patent/PH12020500101A1/en unknown
- 2020-09-15 US US17/021,345 patent/US11883489B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015535259A5 (enExample) | ||
| US11883489B2 (en) | Mucosal adjuvants and delivery systems | |
| KR102103606B1 (ko) | 백신 조성물 | |
| Riese et al. | Intranasal formulations: promising strategy to deliver vaccines | |
| Li et al. | Adjuvantation of influenza vaccines to induce cross-protective immunity | |
| JP2010105968A5 (enExample) | ||
| JP2016117757A (ja) | 免疫応答を増強するワクチンベクターおよび方法 | |
| Böhles et al. | Vaccines against human diarrheal pathogens: current status and perspectives | |
| RU2016110576A (ru) | Бактериальная вакцина и способы ее получения | |
| CN111065417A (zh) | 免疫原性组合物 | |
| Santamarina-Fernández et al. | Pseudomonas aeruginosa Vaccine Development: Lessons, Challenges, and Future Innovations | |
| Jeon et al. | Scalable production and immunogenicity of a cholera conjugate vaccine | |
| WO2021219047A1 (zh) | 一种增强蛋白/肽抗原免疫原性的方法 | |
| Ottolini | Current and future use of vaccines for viral and bacterial respiratory tract infections | |
| Li et al. | Adjuvantation of Influenza Vaccines to Induce Cross-Protective Immunity. Vaccines 2021, 9, 75 | |
| Hargis et al. | Mucosal adjuvants and delivery systems | |
| RU2601158C1 (ru) | ШТАММЫ ВИДА Streptococcus pneumoniae (ВАРИАНТЫ) И СПОСОБ ПОЛУЧЕНИЯ ИЗ НИХ ПРОТЕКТИВНОЙ БЕЛОКСОДЕРЖАЩЕЙ ФРАКЦИИ, ОБЛАДАЮЩЕЙ ВНУТРИВИДОВОЙ ИММУНОГЕННОЙ АКТИВНОСТЬЮ | |
| MR et al. | [Evaluation of the Immunogenic effect of lipopolysaccharide [LPS] and protein fractions of Legionella pneumophila in challenging with lethal dose of this bacterium in mice] | |
| HK1214507B (en) | Novel mucosal adjuvants and delivery systems | |
| CN106729696A (zh) | 一种罗非鱼源无乳链球菌荚膜多糖疫苗的制备方法及其应用 |